BDBM652545 N5-((6-(3-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyridin-3- yl)methyl)isoquinoline-1,5-diamine::US20240059691, Example 1279

SMILES Cc1nnc2CN(CCn12)c1ccc(CNc2cccc3c(N)nccc23)cn1

InChI Key InChIKey=SXVRJEWRROULBO-UHFFFAOYSA-N

Data  5 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 652545   

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652545(US20240059691, Example 1279 | N5-((6-(3-methyl-5,6...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652545(US20240059691, Example 1279 | N5-((6-(3-methyl-5,6...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652545(US20240059691, Example 1279 | N5-((6-(3-methyl-5,6...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652545(US20240059691, Example 1279 | N5-((6-(3-methyl-5,6...)
Affinity DataIC50: 200nMAssay Description:In vitro inhibition of Factor XIIa was determined using an IC50 assay based on standard literature methods (see e.g Baeriswyl et al., ACS Chem. Biol....More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652545(US20240059691, Example 1279 | N5-((6-(3-methyl-5,6...)
Affinity DataIC50: 6.50E+3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent